Gastroesophageal Adenocarcinoma Clinical Trials

42 clinical trials for Gastroesophageal Adenocarcinoma across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma — RECRUITING · PHASE2
• Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) — RECRUITING · PHASE1
• Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) — RECRUITING · PHASE1
• AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas — RECRUITING · PHASE2
• Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels — RECRUITING · PHASE2
• Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease — RECRUITING · PHASE1
• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma — RECRUITING · PHASE2
• Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma — RECRUITING · PHASE1
• Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients — RECRUITING · PHASE2
• A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers — RECRUITING · PHASE1
• Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) — RECRUITING · PHASE1
• A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer — RECRUITING · PHASE1
• AACR ADAPTIVE BIOMARKER-DRIVEN ORGAN PRESERVATION TRIAL IN GASTROESOPHAGEAL ADENOCARCINOMAS — RECRUITING
• ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA — RECRUITING · PHASE2
• A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY OF SONESITATUG VEDOTIN IN COMBINATION WITH FLUOROPYRIMIDINE WITH OR WITHOUT RILVEGOSTOMIG IN FIRST-LINE CLAUDIN18.2-POSITIVE, HER2-NEGATIVE, ADVANCED/METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (CLARITY-GASTRIC 02) — RECRUITING · PHASE3
• A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma — RECRUITING · PHASE2
• A MASTER PROTOCOL FOR AN OPEN-LABEL, MULTI-DRUG, MULTI-CENTER, PHASE II PLATFORM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF NOVEL AGENTS OR COMBINATIONS AS PERIOPERATIVE TREATMENT IN PARTICIPANTS WITH LOCALLY ADVANCED RESECTABLE GASTROESOPHAGEAL ADENOCARCINOMA (GEMINI-PERIOP GC) — RECRUITING · PHASE2
• Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ — RECRUITING · PHASE2
• A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF MK-2870 VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN 3L+ ADVANCED/METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA (GASTRIC ADENOCARCINOMA, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, AND ESOPHAGEAL ADENOCARCINOMA) — RECRUITING · PHASE3
• PHASE 2 STUDY OF ZW25 PLUS FIRST-LINE COMBINATION CHEMOTHERAPY IN HER2-EXPRESSING GASTROESOPHAGEAL ADENOCARCINOMA (GEA) — RECRUITING · PHASE2
• Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma — NOT_YET_RECRUITING · PHASE3
• A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) — TERMINATED · PHASE3
• IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma — NOT_YET_RECRUITING · PHASE2
• ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients — TERMINATED · PHASE2
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers — ACTIVE_NOT_RECRUITING · PHASE3
• RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial — NOT_YET_RECRUITING · PHASE2
• Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) — ACTIVE_NOT_RECRUITING · PHASE2
• A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors — NOT_YET_RECRUITING · PHASE1
• RESTAGE (REPURPOSING STATINS TO IMPROVE OUTCOMES IN GASTROESOPHAGEAL CANCER) TRIAL: A PHASE II RANDOMIZED OPEN-LABEL TRIAL OF PERIOPERATIVE SIMVASTATIN PLUS STANDARD-OF-CARE SYSTEMIC THERAPY IN GASTROESOPHAGEAL ADENOCARCINOMA — NOT_YET_RECRUITING · PHASE2
• A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAIVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA — NOT_YET_RECRUITING · PHASE2
• Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study — NOT_YET_RECRUITING · PHASE2
• A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. — TERMINATED · PHASE1
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab — ACTIVE_NOT_RECRUITING · PHASE1
• Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. — TERMINATED · PHASE1
• ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer — WITHDRAWN · PHASE1
• A Study of a Personalized Neoantigen Cancer Vaccine — COMPLETED · PHASE1
• The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): — OTHER · PHASE1
• A Study of Personalized Neoantigen Cancer Vaccines — COMPLETED
• Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma — COMPLETED · PHASE2
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies — COMPLETED · PHASE1
• Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma — TERMINATED · PHASE2
• Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer — COMPLETED · PHASE2

Refine this search